The Role of Norepinephrine in Emotional Processing
NCT00109642 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 216
Last updated 2017-07-02
Summary
This study will examine the role of a brain chemical called norepinephrine in thinking, decision-making, and emotional processing. After norepinephrine is released from a brain cell, it binds to another brain cell's receptor. Some of the receptors it binds to are called alpha-2 adrenergic receptors. This study will use medicines called yohimbine and guanfacine to look at the function of norepinephrine in the brain when it binds to the alpha-2 adrenergic receptors. Yohimbine increases norepinephrine's function and guanfacine decreases its function.
Healthy volunteers between 20 and 50 years of age who do not have heart disease, high blood pressure, psychiatric illness, or other serious medical conditions and who are not allergic to lactose may be eligible for this study. Candidates are screened with a medical and psychiatric history, physical examination, neuropsychological testing, blood and urine tests and electrocardiogram. Women are screened with a urine pregnancy test.
Participants are given a pill of yohimbine, guanfacine, or placebo and undergo the following tests and procedures:
* Blood pressure and heart rate measurements: Blood pressure and heart rate are measured before the medication is taken and several times after.
* Blood draws: Blood is drawn before the medicine is taken and 90 minutes after to measure levels of norepinephrine and the hormone cortisol.
* Neurocognitive testing: Participants do neurocognitive tasks on the computer for up to 90 minutes. The tasks involve looking at pictures or words on a screen and responding according to instructions given.
* Magnetic resonance imaging (MRI): Patients may undergo neurocognitive testing MRIs. This test uses a strong magnetic field and radio waves to show changes in brain activity. The subject lies on a table that slides into a narrow cylinder (the MRI scanner). Images of the brain are obtained while the subject performs the computer tasks.
Conditions
- Psychopathy
- Mental Disorders
Sponsors & Collaborators
-
National Institute of Mental Health (NIMH)
lead NIH
Eligibility
- Min Age
- 20 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2005-04-26
- Primary Completion
- 2009-03-15
- Completion
- 2009-03-15
Countries
- United States
Study Locations
More Related Trials
-
Study of the Effects of Mecamylamine and Varenicline in Schizophrenia
NCT00455650 ·Status: COMPLETED ·Phase: NA
-
Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia
NCT01555697 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
NCT00942981 ·Status: COMPLETED
-
Will Decreased Noradrenergic Activity Normalize Information Processing in Patients With Schizophrenia?
NCT00206986 ·Status: COMPLETED ·Phase: NA
-
Effect of Memantine on ERP in Early Schizophrenia and Healthy Subjects
NCT02233556 ·Status: UNKNOWN ·Phase: NA
-
Tryptophan-Kynurenine Pathway Metabolism in the Pathophysiology of Cognitive Impairment in Schizophrenia.
NCT07162467 ·Status: ENROLLING_BY_INVITATION
-
Imaging of Brain Receptors in Healthy Volunteers and in Patients With Schizophrenia
NCT00061789 ·Status: COMPLETED ·Phase: PHASE2
-
Reactivity of the Vestibular System to Caloric Vestibular Stimulation in Schizophrenia
NCT03048370 ·Status: COMPLETED ·Phase: NA
-
Characterization of Emotional Processing of Information in Bipolar Disorder and Schizophrenic Patients
NCT02841345 ·Status: UNKNOWN ·Phase: NA
-
Neural Oscillations as Genetic and Functional Biomarkers in Normal and Disease States
NCT01425671 ·Status: COMPLETED
-
Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism
NCT00463346 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacology of Cognition in Schizotypal Personality Disorder
NCT00353379 ·Status: TERMINATED ·Phase: PHASE4
-
The Role of Nitric Oxide in Cognition in Schizophrenia
NCT02906553 ·Status: COMPLETED ·Phase: NA
-
Memantine add-on for Cognitive and Negative Symptoms of Schizophrenia
NCT02001103 ·Status: UNKNOWN ·Phase: PHASE3
-
Stem Cell Research on Subjects at Genetic High Risk for Schizophrenia
NCT01943175 ·Status: COMPLETED
-
Huperzine for Cognitive and Functional Impairment in Schizophrenia
NCT00963846 ·Status: COMPLETED ·Phase: PHASE2
-
Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia
NCT00469664 ·Status: UNKNOWN ·Phase: PHASE4
-
Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia
NCT00148590 ·Status: TERMINATED ·Phase: PHASE3
-
Neuroimaging Studies of Neurophysiological Phenotypes in Schizophrenia
NCT01036568 ·Status: COMPLETED
-
Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism
NCT02675530 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Modafinil on Brain Function in Patients With Schizophrenia
NCT00057707 ·Status: COMPLETED ·Phase: PHASE1
-
Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169039 ·Status: TERMINATED ·Phase: PHASE4
-
Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008)
NCT00934466 ·Status: COMPLETED ·Phase: PHASE1
-
Relation of Catechol-O-methyltransferase (COMT) Genotype and Response to Cognitive Remediation Schizophrenia
NCT00664274 ·Status: UNKNOWN ·Phase: NA
-
Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia
NCT00509067 ·Status: COMPLETED ·Phase: PHASE2